Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...

Related Keywords

Australia ,Brisbane ,Queensland ,United States ,Dallas ,Texas ,American ,Robert Kern ,Anders Cervin ,Kathryn Morris ,Centre For Clinical Research ,Linkedin ,Twitter ,Lyra Therapeutics Inc ,American Rhinologic Society ,Nasdaq ,Lyra Therapeutics ,Otolaryngology Spring Meetings ,Professor Chair ,Clinical Research ,Royal Brisbane ,Hospital Campus ,Queensland Australia ,Chief Medical Officer ,American Rhinologic ,Mental Component Summary ,Private Securities Litigation Reform Act ,Annual Report ,Nc ,